United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

On Monday, BofA Securities analyst Greg Harrison upgraded United Therapeutics Corporation (NASDAQ:UTHR) from Underperform to Neutral, setting a price target of $314.00 for the company’s shares.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 16, 2025--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results ...

Liquidia Corporation (NASDAQ:LQDA), a $1.13 billion market cap pharmaceutical company based in North Carolina, has initiated a patent infringement lawsuit against United Therapeutics (NASDAQ:UTHR ...

Liquidia Corporation (NASDAQ:LQDA), a $1.13 billion market cap pharmaceutical company based in North Carolina, has initiated a patent infringement lawsuit against United Therapeutics (NASDAQ:UTHR) ...

Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium An annual update of the preliminary baseline data from the TETON ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...